Local delivery of checkpoints antibodies

Human Vaccines and Immunotherapeutics

Volumn 13, Issue 1, 2017, Pages 245-248

  Wang, Chao ^a,b   Ye, Yanqi ^a,b   Gu, Zhen ^a,b,c  

^a Biomedical Research Imaging Center   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

biomaterials; cancer immunotherapy; drug delivery; immune checkpoint inhibitors; microneedle

Indexed keywords

ATEZOLIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; HYALURONIC ACID; IMMUNOMODULATING AGENT; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; ANTIBODY; IMMUNOLOGIC FACTOR;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; HUMAN; IMMUNOMODULATION; MOLECULARLY TARGETED THERAPY; NONHUMAN; NOTE; RECEPTOR BLOCKING; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; IMMUNOLOGY; IMMUNOTHERAPY; MEDICAL RESEARCH; NEOPLASMS; PROCEDURES; TRENDS;

ANTIBODIES; BIOMEDICAL RESEARCH; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84991278237     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1223000     Document Type: Note

References (33)

1. Klevorn LE, Teague RM. Adapting Cancer Immunotherapy Models for the Real World. Trends Immunol 2016; 37:354-63; PMID:27105824
2. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348:56-61
3. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer:past, present, and future. J Clin. Invest 2015; 125:3384-91; PMID:26325035; http://dx.doi.org/10.1172/JCI80011
4. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015; 14:561-84; PMID:26228759; http://dx.doi.org/10.1038/nrd4591
5. Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, Hadrup SR, van der Minne CE, Schotte R, Spits H. Neoantigen landscape dynamics during human melanoma–T cell interactions. Nature 2016; 536:91-5; PMID:27350335
6. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy:Mechanisms, response biomarkers, and combinations. Sci Transl Med 2016; 8:328rv4; PMID:26936508; http://dx.doi.org/10.1126/scitranslmed.aad7118
7. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372:2521-32; PMID:25891173; http://dx.doi.org/10.1056/NEJMoa1503093
8. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med 2015; 372:320-30; PMID:25399552; http://dx.doi.org/10.1056/NEJMoa1412082
9. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette G. P, Meyer N, Giguere JK, Agarwala SS, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372:2006-17; PMID:25891304; http://dx.doi.org/10.1056/NEJMoa1414428
10. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373:23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
11. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy:a single-arm, multicentre, phase 2 trial. Lancet 2016; 387:1909-0
12. Mellati M, Eaton KD, Brooks-Worrell BM, Hagopian WA, Martins R, Palmer JP, Hirsch IB. Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes. Diabetes Care 2015; 38:e137-8; PMID:26116720; http://dx.doi.org/10.2337/dc15-0889
13. Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016; 13:473-86; PMID:27141885
14. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 2015; 26:2375-91 mdv383; PMID:26371282
15. Buchbinder EI, Hodi FS. Melanoma in 2015:Immune-checkpoint blockade - durable cancer control. Nat Rev Clin Oncol 2016; 13:77-8; http://dx.doi.org/10.1038/nrclinonc.2015.237
16. Jeanbart L, Swartz MA. Engineering opportunities in cancer immunotherapy. Proc Natl Acad Sci USA 2015; 112:14467-72; http://dx.doi.org/10.1073/pnas.1508516112
17. Pitt JM, Vétizou M, Daillère R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca I. G, Chamaillard M, Kroemer G. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer:Tumor-Intrinsic and-Extrinsic Factors. Immunity 2016; 44:1255-69
18. Wang C, Ye Y, Hochu GM, Sadeghifar H, Gu Z. Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody. Nano Lett 2016; 16:2334-40; PMID:26999507; http://dx.doi.org/10.1021/acs.nanolett.5b05030
19. Quinn HL, Kearney MC, Courtenay AJ, McCrudden MTC, Donnelly RF. The role of microneedles for drug and vaccine delivery. Expert Opin Drug Deliv 2014; 11:1769-80; PMID:25020088; http://dx.doi.org/10.1517/17425247.2014.938635
20. Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev 2012; 64:1547-68; PMID:22575858; http://dx.doi.org/10.1016/j.addr.2012.04.005
21. Ye Y, Yu J, Wang C, Nguyen NY, Walker GM, Buse JB, Gu Z. Microneedles integrated with pancreatic cells and synthetic glucose-signal amplifiers for smart insulin delivery. Adv Mater 2016; 28:3115-21; PMID:26928976; http://dx.doi.org/10.1002/adma.201506025
22. Yu J, Zhang Y, Ye Y, DiSanto R, Sun W, Ranson D, Ligler FS, Buse JB, Gu Z. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. Proc Natl Acad Sci USA 2015; 112:8260-5; PMID:26100900; http://dx.doi.org/10.1073/pnas.1505405112
23. Sullivan SP, Koutsonanos DG, Del Pilar Martin M, Lee JW, Zarnitsyn V, Choi SO, Murthy N, Compans RW, Skountzou I, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010; 16:915-20; PMID:20639891; http://dx.doi.org/10.1038/nm.2182
24. Kines RC, Zarnitsyn V, Johnson TR, Pang YYS, Corbett KS, Nicewonger JD, Gangopadhyay A, Chen M, Liu J, Prausnitz MR, et al. Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles. Plos One 2015; 10:e0120797; PMID:25785935
25. Minn AJ, Wherry EJ. Combination cancer therapies with immune checkpoint blockade:convergence on interferon signaling. Cell 2016; 165:272-5
26. Wang C, Sun W, Wright G, Wang A, Gu Z. Inflammation-triggered cancer immunotherapy by programmed delivery of CpG and Anti-PD1 antibody. Adv Mater 2016
27. Sun WJ, Gu Z. Engineering DNA scaffolds for delivery of anticancer therapeutics. Biomaterials Sci 2015; 3:1018-24; http://dx.doi.org/10.1039/C4BM00459K
28. Sun W, Ji W, Hall JM, Hu Q, Wang C, Beisel CL, Gu Z. Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. Angew Chem Int Ed 2015; 54:12029-33; http://dx.doi.org/10.1002/anie.201506030
29. Sun W, Jiang T, Lu Y, Reiff M, Mo R, Gu Z. Cocoon-like self-degradable DNA nanoclew for anticancer drug delivery. J Am Chem Soc 2014; 136:14722-5; PMID:25336272; http://dx.doi.org/10.1021/ja5088024
30. Demaria S, Coleman CN, Formenti SC. Radiotherapy:changing the game in immunotherapy. Trends Cancer 2016; 2:286-94
31. Hu QY, Sun WJ, Wang C, Gu Z. Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev 2016; 98:19-34; PMID:26546751; http://dx.doi.org/10.1016/j.addr.2015.10.022
32. Goldberg MS. Immunoengineering:how nanotechnology can enhance cancer immunotherapy. Cell 2015; 161:201-4
33. Gu L, Mooney DJ. Biomaterials and emerging anticancer therapeutics:engineering the microenvironment. Nat Rev Cancer 2016; 16:56-66; PMID:26694936; http://dx.doi.org/10.1038/nrc.2015.3